Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | ANPEP | P15144 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569221 | 0.87 | PLAU (0.52) | PLAUANPEPGRIN2BMTNR1AMTNR1B | |
| SCHEMBL43699 | 0.84 | IDO1 (0.46) | PLAUANPEPCA1CA2TSHR | |
| SCHEMBL5693079 | 0.77 | PLAU (0.60) | PLAUANPEPGRIN2BMTNR1AMTNR1B | |
| SCHEMBL10382832 | 0.74 | OPRK1 (0.62) | CA1CA2HTR1ACYP19A1 | |
| SCHEMBL24701721 | 0.73 | PLAU (0.56) | PLAUANPEPGRIN2BMTNR1AMTNR1B | |
| SCHEMBL4922138 | 0.73 | PLAU (0.56) | PLAUANPEPGRIN2BMTNR1AMTNR1B | |
| SCHEMBL9163628 | 0.73 | PLAU (0.56) | PLAUANPEPGRIN2BMTNR1AMTNR1B | |
| SCHEMBL895905 | 0.73 | PLAU (1.00) | PLAUANPEPCA1CA2 | |
| SCHEMBL17151026 | 0.73 | PLAU (0.56) | PLAUANPEPGRIN2BMTNR1AMTNR1B | |
| SCHEMBL291460 | 0.73 | ANPEP (0.57) | PLAUANPEPGRIN2BMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376427-B1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-8969367-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969370-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140329845-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8703791-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140031380-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130345466-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8497287-B2 | Aminotetralin compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8492399-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8486958-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-06-11 | — | — | US | disclosed |
| US-6368573-B1 | MEASURING MYOCARDIAL FUNCTION IN MAMMAL | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-0564520-A1 | USE OF CERTAIN GLUTARIMIDE DERIVATIVES IN THE TREATMENT OF DEPRESSION AND MANIA | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-10-13 | — | — | EP | disclosed |
| WO-1992011011-A1 | USE OF CERTAIN GLUTARIMIDE DERIVATIVES IN THE TREATMENT OF DEPRESSION AND MANIA | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-09 | — | — | WO | disclosed |
| EP-0492021-A1 | Use of certain 1,2-benzoisothiazol-3(2H)-1,1-dioxide derivatives in the treatment of depression and mania | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-5034381-A | Antagonist | CIBA-GEIGY CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
| EP-0374097-A2 | Use of peptide isosteres as retroviral protease inhibitors | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0374098-A2 | Inhibitors of retroviral proteases | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |
| EP-0323807-A2 | Certain 2-substituted adenosine derivatives | CIBA-GEIGY AG (CH) | 1989-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149465-A1 | AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | PLAU 3638/4885ANPEP 566/4885GRIN2B 145/4885 |
| US-20090149535-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | PLAU 3048/4885ANPEP 504/4885GRIN2B 294/4885 |
| US-20130345466-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | PLAU 3518/4885ANPEP 995/4885GRIN2B 302/4885 |
| US-20140329845-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | PLAU 3048/4885ANPEP 504/4885GRIN2B 294/4885 |
| US-20140031380-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | PLAU 3048/4885ANPEP 504/4885GRIN2B 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.